Oncolytics Biotech Files 6-K

Ticker: ONCY · Form: 6-K · Filed: Nov 4, 2025 · CIK: 1129928

Oncolytics Biotech INC 6-K Filing Summary
FieldDetail
CompanyOncolytics Biotech INC (ONCY)
Form Type6-K
Filed DateNov 4, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, routine-report

Related Tickers: ONCY

TL;DR

ONCOLYTICS BIOTECH INC. filed a 6-K, standard foreign private issuer report.

AI Summary

Oncolytics Biotech Inc. filed a Form 6-K on November 4, 2025, reporting as a foreign private issuer. The filing indicates the company's principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121, and that it files annual reports under Form 20-F.

Why It Matters

This filing is a routine report for foreign private issuers, providing an update on the company's status and reporting requirements.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new financial or operational information that would typically impact risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934, typically to provide information that the company makes or is required to make public in its home country.

What is the filing date of this 6-K report?

The filing date of this 6-K report is November 4, 2025.

Where are Oncolytics Biotech Inc.'s principal executive offices located?

Oncolytics Biotech Inc.'s principal executive offices are located at 4350 Executive Drive, Suite 325, San Diego, CA 92121.

Does Oncolytics Biotech Inc. file annual reports under Form 20-F or Form 40-F?

Oncolytics Biotech Inc. indicates that it files annual reports under Form 20-F.

Is Oncolytics Biotech Inc. a US-based company?

The filing indicates that the company's business address is a non-US location, and it is identified as a 'Foreign Private Issuer'.

Filing Stats: 332 words · 1 min read · ~1 pages · Grade level 17 · Accepted 2025-11-04 08:11:01

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date November 4, 2025 Kirk Look Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing